• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Patel Jeegar Pravinkumar

    4/17/26 5:24:42 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVMN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Patel Jeegar Pravinkumar

    (Last)(First)(Middle)
    C/O EVOMMUNE, INC.
    1891 PAGE MILL ROAD

    (Street)
    PALO ALTO CALIFORNIA 94304

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Evommune, Inc. [ EVMN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Scientific Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/16/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Employee Stock Option (Right to Buy)$26.7704/16/2026A69,315 (1)04/15/2036Common Stock69,315$0.0069,315D
    Explanation of Responses:
    1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
    Remarks:
    /s/ Gregory S. Moss, Attorney-in-Fact04/17/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $EVMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVMN

    DatePrice TargetRatingAnalyst
    4/7/2026$50.00Outperform
    Oppenheimer
    1/22/2026$42.00Outperform
    Oppenheimer
    1/8/2026$40.00Strong Buy
    Raymond James
    1/6/2026$35.00Buy
    H.C. Wainwright
    12/1/2025$42.00Outperform
    Leerink Partners
    12/1/2025$36.00Overweight
    Morgan Stanley
    12/1/2025Outperform
    William Blair
    12/1/2025$40.00Outperform
    Evercore ISI
    More analyst ratings

    $EVMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patel Jeegar Pravinkumar

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:24:42 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Drew Janice Suzann

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:24:26 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bauer Eugene

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:23:59 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Evommune with a new price target

    Oppenheimer resumed coverage of Evommune with a rating of Outperform and set a new price target of $50.00

    4/7/26 8:50:59 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Evommune with a new price target

    Oppenheimer initiated coverage of Evommune with a rating of Outperform and set a new price target of $42.00

    1/22/26 8:46:17 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Evommune with a new price target

    Raymond James initiated coverage of Evommune with a rating of Strong Buy and set a new price target of $40.00

    1/8/26 8:54:08 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Evommune Inc.

    DEFA14A - Evommune, Inc. (0002044725) (Filer)

    4/21/26 4:06:29 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Evommune Inc.

    DEF 14A - Evommune, Inc. (0002044725) (Filer)

    4/21/26 4:05:36 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Evommune Inc.

    S-1 - Evommune, Inc. (0002044725) (Filer)

    4/17/26 4:05:52 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hopfner Robert Lorne bought $17,350 worth of shares (1,000 units at $17.35) (SEC Form 4)

    4 - Evommune, Inc. (0002044725) (Issuer)

    12/22/25 7:07:35 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

    Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of Evommune's management team and the following two leading experts in migraine: Stewart

    4/6/26 9:00:00 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    – Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

    3/5/26 4:01:00 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evommune Announces $125 Million Private Placement

    Evommune, Inc. ("Evommune" or the "Company") (NYSE:EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about Feb

    2/12/26 8:30:00 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Financials

    Live finance-specific insights

    View All

    Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

    - Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo - 33% placebo-adjusted improvement in EASI at week 12 - 23% of EVO301 patients achieved IGA 0/1 at week 12 - Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of

    2/10/26 7:30:00 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care